Medical/Pharmaceuticals
Insilico Medicine Launches PandaClaw: Empowering Biologists with Agentic AI for Therapeutic Discovery
CAMBRIDGE, Mass., March 23, 2026 /PRNewswire/ -- Insilico Medicine
("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven
drug discovery company, today announced the launch ofPandaClaw, a
transformative new feature of thePandaOmics
2026-03-23 20:30
3162
Cambrex Advances US and European Expansions
EAST RUTHERFORD, N.J., March 23, 2026 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced the completion of initial engineering studies for its new, large-scale active pharmaceutical ingredient (API) manufacturing plant in Charles ...
2026-03-23 20:00
2226
Monash University and ClinChoice Forge Strategic Partnership to Accelerate Clinical Development of Innovative Therapies
MELBOURNE, Australia, March 23, 2026 /PRNewswire/ -- Monash University and ClinChoice Inc, a leading global clinical Contract Research Organization (CRO) focused on innovative therapeutics, today announced a strategic partnership designed to fast-track early-phase clinical trials and bring ground...
2026-03-23 14:15
2784
Belief BioMed and Grand Life Sciences Announced Exclusive Commercial Partnership in the Field of Hemophilia A, Bringing Innovative Gene Therapy to Chinese Patients
SHANGHAI, March 23, 2026 /PRNewswire/ -- Belief BioMed ("BBM") and Grand Life Sciences Group Co., Ltd. ("Grand Life Sciences") today announced an exclusive collaboration agreement. Under the agreement, Belief BioMed will grant Grand Life Sciences the rights to commercialize its investigational pr...
2026-03-23 14:02
2893
Harbour BioMed Reports the Online Publication of Phase I Results for HBM9378 (SKB378/WIN378), a TSLP-Targeting Antibody
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 22, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics focusing on immunology and immune-oncology, today announ...
2026-03-23 11:14
2250
Everest Medicines Enters into Asset Purchase Agreement with Corxel Pharmaceuticals to Develop and Commercialize CARDAMYST™ (Etripamil) Nasal Spray in Greater China
SHANGHAI, March 23, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into an Asset P...
2026-03-23 10:24
2718
Innovent Announces First Participant Dosed of IBI128 (Tigulixostat, XOI) in Phase 3 Clinical Study
SAN FRANCISCO and SUZHOU, China, March 22, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...
2026-03-23 08:00
2238
Dizal Announces Positive Topline Phase 3 Results from WU-KONG28 Study: Evaluating Oral, Once-Daily ZEGFROVY® (Sunvozertinib) vs. Platinum-Containing Chemo Doublet in First-Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutation (exon20ins)
* Treatment with ZEGFROVY® resulted in statistically significant and clinically meaningful improvement in progression free survival (PFS) over platinum-containing chemo doublet * WU-KONG 28 is the first and only phase 3 study to demonstrate meaningful benefits with an oral, once daily, chemo-...
2026-03-21 19:26
4629
Henlius Reports 2025 Results: Sustained Growth in Both Revenue and Profit, Advancing Innovation Validation and Global Operations
SHANGHAI, March 20, 2026 /PRNewswire/ -- Henlius (2696.HK) today announced its annual results for the year ended December 31, 2025. During the reporting period, the Company recorded revenue of RMB 6.6666 billion, representing a year-on-year increase of 16.5%, and net profit of RMB 0.8270 billion....
2026-03-20 21:21
7444
Earendil Labs Announces $787 Million in Financing to Scale AI-Driven Biologics Discovery and Development
WILMINGTON, Del., March 20, 2026 /PRNewswire/ -- Earendil Labs, an AI-driven biotechnology company advancing next-generation biologics, today announced that it has raised$787 million in financing rounds. The investment included participation by a group of leading global investors, including Dimen...
2026-03-20 19:30
3481
HKSH Cancer Centre's Precision Targeting Technologies Leading the Evolution of "Hypofractionation"
Asia's First Study: 5 Sessions of Proton Therapy to Control Early-Stage Prostate Cancer HONG KONG, March 20, 2026 /PRNewswire/ -- HKSH Medical Group (HKSH) today announced the results of Asia's first clinical study on early-stage prostate cancer patients receiving five-session of proton therapy....
2026-03-20 19:10
3590
Antengene Announces 2025 Full-Year Results: First TCE Out-licensing Validates Platform Value and Marks Inflection Point Towards 2026 Profitability
SHANGHAI and HONG KONG, March 20, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) today announced its full-year results for the period ending December 31, 2025, and provided an update on recent business highlights and strategic progress. Dr. Jay Mei, Antengene's...
2026-03-20 17:14
6514
World Oral Health Day 2026: FDI urges governments to turn UN oral health commitments into action
Landmark UN political declaration recognizes oral health as essential to
tackling noncommunicable diseases
GENEVA, March 20, 2026 /PRNewswire/ -- On World Oral Health Day
2026-03-20 16:30
2686
Ribo expands beyond the liver with RiboPepSTAR™ - enabling targeted siRNA delivery to multiple organs
SUZHOU, China and MÖLNDAL, Sweden, March 20, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. ("Ribo" or "the Company", Hong Kong Stock Exchange code: 6938) had been invited to give a speech at the RNA Leaders Europe Conference in Vienna, Austria on March 19th, one of the top oligonucleot...
2026-03-20 14:44
3161
MGI Tech and NUS Pharmacy and Pharmaceutical Sciences Announce Collaboration on DCS Lab to Accelerate Multi-Omics Innovation in Pharmaceutical Sciences
SINGAPORE, March 20, 2026 /PRNewswire/ -- MGI Tech Singapore Pte. Ltd. ("MGI"), a company dedicated to developing core tools and technologies that drive innovation in life sciences, and the Department of Pharmacy and Pharmaceutical Sciences in the National University of Singapore's Faculty of Sci...
2026-03-20 11:17
4245
Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Triple-Negative Breast Cancer of TROP2/HER3 Bispecific ADC JSKN016
SUZHOU, China, March 20, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) today announced that the first patient has been dosed in a phase III clinical study (JSKN016-301) evaluating JSKN016, a novel TROP2/HER3 bispecific antibody-drug conjugate (ADC) for the treatment of triple-negat...
2026-03-20 10:04
2951
GI Innovation Announces First Clinical Supply Agreement to Explore Combination Therapy for Prostate Cancer
SEOUL, South Korea, March 19, 2026 /PRNewswire/ -- GI Innovation announced on 19th that it has entered into a clinical supply agreement with Johnson & Johnson to evaluate a combination therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) in a phase1b clinical trial. ...
2026-03-20 09:29
2422
D3 Bio to Showcase Its Innovative KRAS Pipeline at AACR 2026, Including an Oral Presentation at Clinical Plenary Session
SHANGHAI, March 20, 2026 /PRNewswire/ -- D3 Bio Inc, a global clinical-stage biotechnology company focused on developing transformative oncology therapeutics, is pleased to announce that five abstracts have been accepted for presentation at the upcoming American Association for Cancer Research (A...
2026-03-20 09:00
3351
Crescel Reports Positive Randomized Controlled Trial Results for Biobotanical Skin Renewal Cream in Rosacea
Study Shows Greater Clinical Improvement vs. Metronidazole-Based Standard of Care with Favorable Tolerability MIAMI BEACH, Fla., March 20, 2026 /PRNewswire/ -- Crescel LLC, an innovative science and technology company, today announced results from a double-blind, randomized, active comparator-c...
2026-03-20 05:39
2696
Woori IO, an OSR Company, Signs NDA with Sinopharm for China Market and Global Multicenter Trials
BELLEVUE, Wash., March 19, 2026 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a healthcare-focused holding company advancing innovative medical technologies, today announced that its subsidiary, Woori IO Co., Ltd. ("Woori IO"), has entered into a mutual non-disclosure agreement ("NDA") with ...
2026-03-19 21:44
3074
Week's Top Stories
Most Reposted
Visa Working Capital Index: Asia Pacific CFOs Call for Flexible, Digital Finance Solutions
[Picked up by 309 media titles]
2026-03-24 14:00HOY Unveils a Powerhouse Line-up of Talent for its Bold New Chapter
[Picked up by 306 media titles]
2026-03-20 09:36
Indonesia's P2P Lending Grows 25%, JULO Strengthens Credit Quality
[Picked up by 300 media titles]
2026-03-26 18:18
MetaOptics progresses on its strategic growth and leadership transition initiatives
[Picked up by 283 media titles]
2026-03-20 08:15ART CENTRAL COMMENCES DISCOVERY-LED ELEVENTH EDITION
[Picked up by 277 media titles]
2026-03-25 16:51
Most Read
Everbright Environment Announces 2025 Annual Results
2026-03-20 23:14
8129
Ten Pao Group Announces 2025 Annual Results
2026-03-20 23:35
7894
FiEE, Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results
2026-03-21 04:05
7892
U Power Limited Announces Closing of $6.0 Million Public Offering
2026-03-21 02:40
7372